134 related articles for article (PubMed ID: 38788029)
1. Clinical inertia in thyrotropin suppressive therapy for low-risk differentiated thyroid cancer: A real-world experience at an endocrine center in Bangkok.
Thewjitcharoen Y; Chatchomchuan W; Wanothayaroj E; Butadej S; Nakasatien S; Krittiyawong S; Rajatanavin R; Himathongkam T
Medicine (Baltimore); 2024 May; 103(21):e38290. PubMed ID: 38788029
[TBL] [Abstract][Full Text] [Related]
2. Assesment of attainment of recommended TSH levels and levothyroxine compliance in differentiated thyroid cancer patients.
Yavuz DG; Yazan CD; Hekimsoy Z; Aydin K; Gokkaya N; Ersoy C; Akalın A; Topaloglu O; Aydogan BI; Dilekci ENA; Alphan Uc Z; Cansu GB; Ozsari L; Iyidir OT; Olgun ME; Keskin L; Mert M; Can B; Gungor K; Galip T; Cantürk Z; Elbuken G; Pekkolay Z; Kutbay NO; Yorulmaz G; Kalkan AT; Unsal YA; Yay A; Karagun B; Bozkur E
Clin Endocrinol (Oxf); 2022 Dec; 97(6):833-840. PubMed ID: 35639050
[TBL] [Abstract][Full Text] [Related]
3. Delayed TSH recovery after dose adjustment during TSH-suppressive levothyroxine therapy of thyroid cancer.
Kim HI; Kim TH; Kim H; Kim YN; Jang HW; Kim JH; Hur KY; Chung JH; Kim SW
Clin Endocrinol (Oxf); 2017 Sep; 87(3):286-291. PubMed ID: 28375573
[TBL] [Abstract][Full Text] [Related]
4. Effects of short-term metformin therapy associated with levothyroxine dose decrement on TSH and thyroid hormone levels in patients with thyroid cancer.
Mousavi Z; Dourandish L; Rokni H; Sadeghi R; Rasoul Zakavi S
Minerva Endocrinol; 2014 Mar; 39(1):59-65. PubMed ID: 24513605
[TBL] [Abstract][Full Text] [Related]
5. Changes within the thyroid axis after long-term TSH-suppressive levothyroxine therapy.
Verburg FA; Smit JW; Grelle I; Visser TJ; Peeters RP; Reiners C
Clin Endocrinol (Oxf); 2012 Apr; 76(4):577-81. PubMed ID: 22017394
[TBL] [Abstract][Full Text] [Related]
6. Changes in TSH levels in athyreotic patients with differentiated thyroid cancer during levothyroxine therapy: influence on dose adjustments.
Grani G; Tumino D; Ramundo V; Ciotti L; Lomonaco C; Armillotta M; Falcone R; Lucia P; Maranghi M; Filetti S; Durante C
J Endocrinol Invest; 2019 Dec; 42(12):1485-1490. PubMed ID: 31203497
[TBL] [Abstract][Full Text] [Related]
7. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
Chen CH; Chen JF; Yang BY; Liu RT; Tung SC; Chien WY; Lu YC; Kuo MC; Hsieh CJ; Wang PW
J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
[TBL] [Abstract][Full Text] [Related]
8. Thyrotropin Suppressive Therapy for Low-Risk Small Thyroid Cancer: A Propensity Score-Matched Cohort Study.
Park S; Kim WG; Han M; Jeon MJ; Kwon H; Kim M; Sung TY; Kim TY; Kim WB; Hong SJ; Shong YK
Thyroid; 2017 Sep; 27(9):1164-1170. PubMed ID: 28699428
[TBL] [Abstract][Full Text] [Related]
9. Effect of thyrotropin suppressive therapy on heart rate variability and QT dispersion in patients with differentiated thyroid cancer.
Liu C; Lv H; Li Q; Fu S; Tan J; Wang C; Wang X; Ma Y
Medicine (Baltimore); 2020 Jul; 99(28):e21190. PubMed ID: 32664162
[TBL] [Abstract][Full Text] [Related]
10. Levothyroxine Cessation After Thyroid Lobectomy for Papillary Thyroid Cancer Can Be Achieved at the Same Rate as that for Benign Tumors Regardless of the Duration of Thyroid-stimulating Hormone Suppression.
Na YM; Cho JS; Park MH
Anticancer Res; 2021 Nov; 41(11):5713-5721. PubMed ID: 34732444
[TBL] [Abstract][Full Text] [Related]
11. Changes in Prescription Routines for Treating Hypothyroidism Between 2001 and 2015: An Observational Study of 929,684 Primary Care Patients in Copenhagen.
Medici BB; Nygaard B; la Cour JL; Grand MK; Siersma V; Nicolaisdottir DR; Lind B; Olivarius NF; Andersen CL
Thyroid; 2019 Jul; 29(7):910-919. PubMed ID: 31017048
[No Abstract] [Full Text] [Related]
12. The relationship of preconception thyrotropin levels to requirements for increasing the levothyroxine dose during pregnancy in women with primary hypothyroidism.
Abalovich M; Alcaraz G; Kleiman-Rubinsztein J; Pavlove MM; Cornelio C; Levalle O; Gutierrez S
Thyroid; 2010 Oct; 20(10):1175-8. PubMed ID: 20860419
[TBL] [Abstract][Full Text] [Related]
13. Liquid liothyronine to obtain target TSH in differentiated thyroid cancer patients.
Trimboli P; Centanni M; Virili C
Endocr J; 2016 Jun; 63(6):563-7. PubMed ID: 27000530
[TBL] [Abstract][Full Text] [Related]
14. Effects of Chronic Suppression or Oversuppression of Thyroid-Stimulating Hormone on Psychological Symptoms and Sleep Quality in Patients with Differentiated Thyroid Cancer.
Altuntaş SÇ; Hocaoğlu Ç
Horm Metab Res; 2021 Oct; 53(10):683-691. PubMed ID: 34607367
[TBL] [Abstract][Full Text] [Related]
15. Frequency of Thyroid Hormone Replacement After Lobectomy for Differentiated Thyroid Cancer.
Schumm MA; Lechner MG; Shu ML; Ochoa JE; Kim J; Tseng CH; Leung AM; Yeh MW
Endocr Pract; 2021 Jul; 27(7):691-697. PubMed ID: 33642257
[TBL] [Abstract][Full Text] [Related]
16. Degree of thyrotropin suppression in differentiated thyroid cancer without recurrence or metastases.
Kamel N; Güllü S; Dağci Ilgin S; Corapçioğlu D; Tonyukuk Cesur V; Uysal AR; Başkal N; Erdoğan G
Thyroid; 1999 Dec; 9(12):1245-8. PubMed ID: 10646665
[TBL] [Abstract][Full Text] [Related]
17. Trabecular bone deterioration in differentiated thyroid cancer: Impact of long-term TSH suppressive therapy.
Hawkins Carranza F; Guadalix Iglesias S; Luisa De Mingo Domínguez M; Martín-Arriscado Arroba C; López Álvarez B; Allo Miguel G; Martínez Díaz-Guerra G
Cancer Med; 2020 Aug; 9(16):5746-5755. PubMed ID: 32583973
[TBL] [Abstract][Full Text] [Related]
18. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer.
Biondi B; Cooper DS
Thyroid; 2010 Feb; 20(2):135-46. PubMed ID: 20151821
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of adequacy of levo-thyroxine dosage in patients with differentiated thyroid carcinoma: correlation between morning and afternoon TSH determination.
Conte L; Monti E; Gay S; Marroni P; Adorno A; Mittica M; Mussap M; Giusti M
J Endocrinol Invest; 2018 Oct; 41(10):1193-1197. PubMed ID: 29476411
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the strategy of LT4 prescribing and TSH monitoring for thyroid carcinoma after lobectomy.
Wang Z; Angell TE; Sun W; Qin Y; He L; Dong W; Zhang D; Zhang T; Shao L; Lv C; Zhang P; Guan H; Zhang H
Ann Transl Med; 2020 Oct; 8(19):1238. PubMed ID: 33178770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
